Core Viewpoint - The report from Citi highlights that for the Chinese healthcare sector, profit delivery will be more important than valuation expansion by 2026, with WuXi AppTec (603259) expected to outperform its peers [1] Group 1: Company Performance - WuXi AppTec is identified as the top pick in the Chinese CRO/CDMO industry, maintaining a "buy" rating with a target price of HKD 143.4 [1] - The company anticipates a revenue growth of 9% in Q4 2025, with a Non-IFRS year-on-year growth of 36%, exceeding market expectations by 2% and 3% respectively [1] - The strong performance is attributed to the integrated CRDMO model and robust growth in the TIDES business, alongside China's competitive position in the global small molecule supply chain [1] Group 2: Market Position and Growth - The valuation of the Chinese healthcare sector has significantly recovered over the past year, leading to a focus on profit realization as the main driver for stock prices in 2026 [1] - WuXi AppTec shows stronger visibility in profit growth compared to peers, with a 41% year-on-year increase in order reserves for the first three quarters of 2025, significantly above the global average of approximately 14% [1] - The company is expected to continue leading in order growth rates compared to global peers in 2026 [1] Group 3: Financial Metrics - WuXi AppTec's return on equity (ROE) is projected to be 24% in 2025, significantly higher than the 6% to 16% range of global peers, indicating a strong competitive advantage in the global pharmaceutical outsourcing market [2] - The earnings forecast for WuXi AppTec from 2025 to 2027 remains unchanged, with confidence in achieving high double-digit growth in adjusted Non-IFRS net profit for 2026, exceeding market expectations by approximately 15% [2]

Group 1 - The core view is that for the Chinese healthcare sector, profit delivery will be more important than valuation expansion by 2026, with WuXi AppTec (02359) expected to outperform its peers [1] - WuXi AppTec is identified as the top choice in the Chinese CRO/CDMO industry, with a maintained "outperform" rating and a target price of HKD 143.4 [1] - The company anticipates a revenue growth of 9% in Q4 2025, with a Non-IFRS year-on-year growth of 36%, exceeding market consensus by 2% and 3% respectively [1] Group 2 - WuXi AppTec's strong order reserve growth of 41% year-on-year for the first three quarters of 2025 is significantly higher than the global average of approximately 14% [1] - The company is expected to maintain a high return on equity (ROE) of 24% in 2025, which is substantially above the global peer range of 6% to 16% [2] - The firm is confident that WuXi AppTec's adjusted Non-IFRS net profit will achieve high double-digit growth in 2026, outperforming market expectations by about 15% [2]

Investment Rating - The report indicates a positive outlook for WuXi Biologics, suggesting that the company will outperform its peers in the biopharmaceutical CDMO sector in 2026 [5]. Core Insights - WuXi Biologics is expected to experience a reacceleration in growth in 2026, driven by three main catalysts: the growth momentum from dual/multi-antibody projects, a strong project intake in 2025 with a net addition of 128 projects, and a reduction in valuation pressure from geopolitical factors [5][8]. - The non-XDC business of WuXi Biologics is anticipated to accelerate in 2026, contrary to market expectations, returning the company to a multi-engine growth trajectory [6]. - The company’s dual/multi-antibody projects are projected to be a significant growth driver, with a 30% year-on-year increase in project numbers for 2025, outpacing the overall company growth rate of 16% [7]. Summary by Sections Company Overview - WuXi Biologics is a leading global contract research, development, and manufacturing organization (CRDMO) that provides end-to-end solutions to help partners develop biopharmaceuticals from concept to commercialization [10]. Financial Performance - As of January 9, 2026, the stock price is HKD 37.06, with a market capitalization of USD 19.65 billion. The average daily trading volume over the past three months is USD 138.43 million [13]. - The revenue breakdown shows that biopharmaceuticals account for 88.8% of total revenue, while WuXi XDC contributes 11.2% [11]. Growth Drivers - The report highlights that the strong project intake in 2025, with 128 new projects, sets a solid foundation for faster growth in 2026 compared to 2025 [5][8]. - The profitability outlook is favorable due to the optimization of the project structure towards complex dual/multi-antibody projects, which is expected to enhance profit margins [7].

Core Points - Curia Global, Inc. has been awarded the "Manufacturer of the Year" title by the Massachusetts Legislative Manufacturing Caucus for its sterile formulation facility in Burlington, Massachusetts [1][2] - The Burlington facility has been a crucial part of Curia's global network since 2010, focusing on the production of vials and pre-filled syringes for late-stage clinical trials and commercial products [1][2] - The facility is recognized for its capabilities in handling solvent-based processes, high-viscosity products, and controlled substances, and it includes an on-site process development laboratory [1][2] Company Overview - Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience, operating a network of 20 global facilities and employing 3,200 staff [3] - The company provides comprehensive services from discovery to commercialization in small molecule drugs, active pharmaceutical ingredients (APIs), sterile formulations, and biologics, including integrated regulatory, analytical testing, and sterile filling capabilities [3] - Curia aims to accelerate research processes and improve patient lives through its scientific and technical expertise [3]